Eli Lilly's once-weekly insulin efsitora meets primary endpoints in Phase 3 trials for type 2 diabetes.

From Nasdaq: 2025-06-22 21:31:00

Eli Lilly and Co. released results from Phase 3 trials for once-weekly insulin efsitora in adults with type 2 diabetes. Efsitora met primary endpoints in all trials, showing non-inferior A1C reduction compared to daily basal insulin. Efsitora reduced A1C by 1.31% in QWINT-1, 0.86% in QWINT-3, and 1.07% in QWINT-4. Safety profile was comparable to other daily basal insulin therapies, with fewer hypoglycemic events. Lilly plans to submit efsitora for global regulatory approval by the end of the year. Visit rttnews.com for more health news.



Read more at Nasdaq: Lilly’s Once-Weekly Insulin Efsitora Meets Main Goals Across Three Phase 3 Trials In Type 2 Diabetes